Nicox provides business update at Ordinary and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Nicox provides business update at Ordinary and Extraordinary Shareholder Meetings

...................................

  • Lead clinical candidates Vesneo(TM) and AC-170 on track for NDA submission in the United States
  • New preclinical nitric oxide-donating programs moving forward

...................................

 SOPHIA ANTIPOLIS, France, June 3, 2015 (GLOBE NEWSWIRE) --

Nicox S.A. (Euronext Paris: FR0000074130, COX), the international ophthalmic company, today provided an update ahead of its Ordinary and Extraordinary Shareholder Meetings, convened today, June 3, 2015, at 2 pm CET in Sophia Antipolis (France). The updated Company presentation provided at the Shareholder Meetings will be available by 12 pm CET today in the News & Media / Presentations & Webcasts section of Nicox's website ( www.nicox.com ).

Lead clinical candidates Vesneo(TM) and AC-170 on track for NDA submission with the FDA

Nicox's licensee Bausch + Lomb (a wholly owned subsidiary of Valeant Pharmaceuticals International Inc.) remains on track to submit a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Vesneo(TM) (latanoprostene bunod). An announcement is expected once the NDA submission has been accepted for filing by the FDA, which normally takes place around 60 days following submission.

The NDA submission for AC-170, a novel formulation of cetirizine developed for the treatment of ocular itching associated with allergic conjunctivitis, also remains on track. Nicox's objective is to obtain FDA approval by the end of 2016.

Nicox's advanced pipeline also features two pre-MAA (Marketing Authorization Application) candidates in Europe: AzaSite ® for bacterial conjunctivitis and BromSite(TM) for pain and inflammation after cataract surgery. Nicox now expects to submit European MAAs for both candidates by the end of the first half of 2016.

Preclinical programs moving forward

Based on the positive phase 3 results for Vesneo(TM) and increased interest in the potential of nitric oxide (NO)-donors in ophthalmology, Nicox's Board of Directors has selected NCX 470 as the Company's lead follow-on glaucoma candidate for internal development. NCX 470 is a novel nitric oxide-donating bimatoprost discovered in Nicox's research laboratories which showed promising results at ARVO 2015 1 in several preclinical models of glaucoma and ocular hypertension (see Nicox press release dated May 11, 2015). Bimatoprost, marketed under the brand name Lumigan ®2 , is one of the leading products in the class of prostaglandin analogs, the most widely used class of Intra-Ocular Pressure (IOP) lowering drugs. The Company will now advance NCX 470 toward clinical-stage trials.

Nicox's research team will also continue to work on two other nitric oxide donor programs:

  • Nitric oxide-donating steroids target steroid-treatable front and / or back of the eye diseases such as Diabetic Macular Edema (DME). Two potential candidate compounds, NCX 434 and NCX 422, have been selected and Nicox expects to commence pre-Investigational New Drug (IND) development activities with at least one of these candidates.
  • Next-generation stand-alone nitric oxide-donors are designed to enable the optimization of nitric oxide dosing, targeting glaucoma and other ophthalmic indications. A lead compound, NCX 667, has already shown promising preclinical results and is now being optimized. The NCX 667 results were selected by the ARVO 2015 Annual Meeting Program Committee as a 'Hot Topic', representing the newest and most innovative research being conducted 3 . 

In addition, Nicox has decided to advance its nanocrystalline fluticasone propionate, formerly known as AC-155, for the treatment of blepharitis, under the code name NCX 4251. This indication has strong commercial potential as there are currently no treatments specifically approved for the condition. Nicox believes the novel nanocrystalline form may be suited to sustained availability of the drug on the eyelid margin. Because of the extensive data already available on fluticasone, NCX 4251 would be expected to go directly into phase 2 clinical trials following toxicity studies and IND filing, pending IND approval by the FDA.

Dr. Michael Bergamini, Chief Scientific Officer and Executive Vice President at Nicox, commented: "The success of Vesneo(TM) in Phase 3 clinical studies has underlined the therapeutic interest of our nitric oxide donors in ophthalmology. Nicox's research expertise and track record in this field is now focused on discovering the next generation of compounds for glaucoma, led by NCX 470 and the next generation of stand-alone nitric oxide-donors, and for other areas of significant need in ophthalmology such as Diabetic Macular Edema."

2015 Ordinary and Extraordinary Shareholder Meetings

Based on the proxy votes which have already been registered, all the resolutions of the Ordinary and Extraordinary Shareholder Meetings are expected to be approved. The detailed resolutions can be found on Nicox's website in the Investor Information / Shareholder Meetings section. The minutes of the Ordinary and Extraordinary Shareholder Meetings, as well as the results of the vote, will be posted in the same section of the website by the end of today.

...................................

References

  1. Impagnatiello F, Bastia E, Toris CB, Krauss AH, Prasanna G, Ongini E, NCX 470, a nitric oxide (NO)-donating bimatoprost lowers intraocular pressure in rabbits, dogs and non-human primate models of glaucoma, ARVO 2015 Annual Congress, Abstract No. 5809.
  2. Lumigan is a registered trademark of Allergan, Inc.
  3. Bastia E, Impagnatiello F, Almirante N, Lanzi C, Masini E, Toris C, Ongini E, NCX 667, a novel nitric oxide (NO) donor lowers intraocular pressure (IOP) in ocular normotensive and hypertensive eyes of rabbits and non-human primates, ARVO 2015 Annual Congress, Abstract No. 1999-D0242.

...................................

About Nicox

Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an international commercial-stage company focused on the ophthalmic market. With a heritage of innovative R&D, business development and marketing expertise, we are building a diversified portfolio of ophthalmic products that can help people to enhance their sight.

Nicox's advanced pipeline features two pre-NDA candidates (Vesneo(TM) for glaucoma, partnered with Bausch + Lomb / Valeant and AC-170 for allergic conjunctivitis) as well as two pre-MAA candidates (AzaSite ® for bacterial conjunctivitis and BromSite(TM) for pain and inflammation after cataract surgery). The Group operates directly in six countries, including the United States. It has proprietary commercial operations in Europe's five largest markets complemented by an expanding international network of distributors.

Nicox is headquartered in France and has more than 120 staff worldwide. It is listed on Euronext Paris (Category B: Mid Caps) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its commercial products or pipeline, please visit www.nicox.com .

Upcoming events
Financial and business conferences
June 1-4 Jefferies Healthcare Conference New York, US  Presentation: June 4, 2015 at 11.30 am EDT
June 25 Kepler Biotech Day Paris, France  
       
Scientific conferences
June 6-9 European Society of Ophthalmology (SOE)  Vienna, Austria  
June 28-30  MaculArt Paris, France Booth 17
Analyst coverage        
Bryan, Garnier & Co  Hugo Solvet Paris    
Stifel Max Herrmann London 
Invest Securities Martial Descoutures  Paris
Contacts  
Nicox Gavin Spencer | Executive Vice President Corporate Development
  Caroline Courme | Communication Manager
  Tel +33 (0)4 97 24 53 43 | communications@nicox.com
   
Media Relations  
   
United Kingdom Jonathan Birt
  Tel +44 7860 361 746 | jonathan.birt@ymail.com
   
France NewCap | Nicolas Merigeau
  Tel +33 (0)1 44 71 94 98 | nicox@newcap.fr
   
United States Argot Partners | Eliza Schleifstein
  Tel +1 (917) 763-8106 | eliza@argotpartners.com
   
Investor Relations  
   
Europe NewCap | Julien Perez | Valentine Brouchot
  Tel +33 (0)1 44 71 94 94 | nicox@newcap.fr
   
United States Argot Partners | Melissa Forst
  Tel +1 (212) 600-1902 | melissa@argotpartners.com

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in the 4 th chapter of the ' Document de référence, rapport financier annuel et rapport de gestion 2014 ' filed with the French Autorité des Marchés Financiers (AMF) on April 10, 2015, which is available on Nicox's website ( www.nicox.com ).

Nicox S.A. Drakkar 2 | Bât D | 2405 route des Dolines | CS 10313 | Sophia Antipolis | 06560 Valbonne | France T: +33 (0)4 97 24 53 00   |   F: +33 (0)4 97 24 53 99

www.nicox.com

Press release http://hugin.info/143509/R/1925893/691065.pdf

HUG#1925893

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DKSH's Vietnam Oncology Pact Carries Real Promise, Risk

Updated Category News Views 58

A cancer-market announcement ought to make investors pause before they reach for a spreadsheet. Specialised Therapeutics and DKSH have signed an exclusive partnership to bring oncology therapies into Vietnam, and the human case is painfully clear: the country recorded an estimated 180,000 new cancer cases and more than 120,000 deaths annually in the 2022 GLOBOCAN data....

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 318

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 140

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 110

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 61

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 455

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 661

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 394

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading

Top 5 Most Recently Viewed Articles

Shaquille O'Neal Empowers Young Leaders with New Scholarship

Updated Category News Views 743

Shaquille O'Neal Champions the Future of Entrepreneurship Full scholarships, elite mentorship, and real-world learning experiences are now within reach for aspiring creators and entrepreneurs, thanks to a groundbreaking initiative launched by Campus, a modern two-year college committed to nurturing the next generation of leaders. This new scholarship program, backed by...

Continue Reading
Investors Take Action: Class Action Lawsuits on the Rise

Updated Category News Views 146

Protecting Your Investments: Class Action Overview Investing in public companies often comes with risks, and sometimes those risks manifest as legal issues. Recently, class action lawsuits have sprung up involving several well-known companies. These lawsuits present opportunities for investors to raise their voices against corporate misconduct and reclaim lost...

Continue Reading
Top Strategies from DealerFire to Enhance Website Engagement

Updated Category News Views 171

Effective Strategies to Reduce Dealership Website Bounce Rates Transforming website visitors into clients is essential for dealerships, and DealerFire offers insightful strategies to enhance website performance effectively. Boosting Page Load Speed The Importance of Speed Website speed plays a critical role in keeping visitors on the site. DealerFire stresses the need to...

Continue Reading
Lassila & Tikanoja's Annual General Meeting Announcement

Updated Category News Views 115

Notice of the Annual General Meeting Lassila & Tikanoja plc has issued a notice regarding the upcoming Annual General Meeting. This meeting serves as an important gathering for shareholders to discuss significant matters concerning the company's future. Meeting Details The Annual General Meeting will take place on Thursday, March 27, 2025, at 4:00 PM, with registration...

Continue Reading
Soapy Joe's Expands Its Reach with 25th Car Wash Location

Updated Category News Views 490

Soapy Joe's Expands Its Reach with 25th Car Wash Location Soapy Joe's Car Wash, a family-owned favorite in the San Diego area, is thrilled to announce the arrival of its 25th location in the community. This new car wash is positioned to provide not only top-notch car cleaning services but also a unique, enjoyable experience for local residents. Grand Opening Celebration...

Continue Reading